Active and machine learning-enhanced discovery of new FGFR3 inhibitor, Rhapontin, through virtual screening of receptor structures and anti-cancer activity assessment.

导出 LinkOut

翻译打印收藏纠错

第一作者： Qingxin,Zeng

第一单位： Department of Thoracic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.

作者： Qingxin,Zeng ^[1] ; Haichuan,Hu ^[1] ; Zhengwei,Huang ^[1] ; Aotian,Guo ^[1] ; Sheng,Lu ^[1] ; Wenbin,Tong ^[2] ; Zhongheng,Zhang ^[3] ; Tao,Shen ^[1]

作者单位： Department of Thoracic Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China. ^[1] Department of Thoracic Surgery, Longyou County People's Hospital, Hangzhou, China. ^[2] Department of Emergency Medicine, Sir Run Run Shaw Hospital, Hangzhou, China. ^[3]

关键词 AI-derived drug discovery FGFR3 inhibitor NSCLC Rhapontin biology evaluation

DOI 10.3389/fmolb.2024.1413214

PMID 38919748

发布时间 2024-06-27

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in molecular biosciences

2024年11卷

1413214页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Active and machine learning-enhanced discovery of new FGFR3 inhibitor, Rhapontin, through virtual screening of receptor structures and anti-cancer activity assessment.

Frontiers in molecular biosciences

相似文献

Frontiers in molecular biosciences

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Active and machine learning-enhanced discovery of new FGFR3 inhibitor, Rhapontin, through virtual screening of receptor structures and anti-cancer activity assessment.

Frontiers in molecular biosciences

相似文献

Frontiers in molecular biosciences

相关期刊

检索历史清除